Skip to content

Safety and efficacy of remimazolam for general anesthesia in elderly patients underwent laparoscopic cholecystectomy - a randomized controlled trial

Safety and efficacy of remimazolam for general anesthesia in elderly patients underwent laparoscopic cholecystectomy - a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0006796
Enrollment
84
Registered
2021-12-02
Start date
2022-03-24
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Group R continuously intravenously injects remimazolam at an injection rate of 6 mg/kg/h to induce general anesthesia. Group P slowly intravenously administers 1.0 -1.5 mg/kg of propofol for 1

Sponsors

Chosun University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Laparoscopic cholecystectomy. Adults over 65 years of age. I, II, III of American Society of Anesthesiologists (ASA) Physical Status classification Patients who voluntarily agreed to participate in this clinical study.

Exclusion criteria

Exclusion criteria: Emergency surgery. Patients with hemodynamic instability Patients with a history of resistance or hypersensitivity to benzodazepine and other anesthetics. Patients with acute narrow-angle glaucoma Neuromuscular disease. Patients with alcohol or drug dependence Patients with chronic renal failure and severe liver disorder (Child Pugh Classification C) Patients with genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption

Design outcomes

Primary

MeasureTime frame
Time of loss of consciousness

Secondary

MeasureTime frame
BIS or entropy score;Time to reach an anesthesia depth score of 50 or less after administration of the study drug (seconds);Blood pressure and heart rate;Frequency of awakening during surgery;Presence of cardiovascular abnormalities (%);Time to open your eyes after discontinuing the administration of the study drug (minutes)

Countries

Korea, Republic of

Contacts

Public ContactSang Hun Kim

Chosun University Hospital

ksh3223@chosun.ac.kr+82-62-220-3578

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026